random-effects model. Heterogeneity was investigated using 
I2, with an I2 of equal to or under 75% used as the cut-off 
for proceeding with meta-analysis [19]. Meta-analyses were 
undertaken using RevMan v.5.4 (Cochrane Collaboration, 
Vienna, Austria) and reported following PRISMA guidance.
A pre-planned sensitivity analysis included only studies 
at low risk of bias for the primary outcome. A further post-
hoc sensitivity analysis was conducted to examine the risk